Video

Examining 10-year postop data on epi-off CXL for keratoconus, ectasia

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|ASCRS

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

Steven Greenstein, MD, of the Cornea and Laser Institute (Teaneck, NJ), reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients who underwent laser refractive surgery.

Read the article: CXL effects remain generally stable 10 years post-treatment

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
Related Content
(Image credit: AdobeStock/Bonsales) Q&A: Natalie Afshari, MD, FACS, on-label pediatric IOLs: turning advocacy into access
July 24th 2025

Q&A: Natalie Afshari, MD, FACS, championing on-label pediatric IOLs: turning advocacy into access

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/iQoncept) Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence
July 23rd 2025

Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

OKYO Pharma receives $1.9 million in non-dilutive funding
July 21st 2025

OKYO Pharma receives $1.9 million in non-dilutive funding

Cloudbreak Pharma reports positive phase 2 results for CBT-004 in vascularized pinguecula
July 21st 2025

Cloudbreak Pharma reports positive phase 2 results for CBT-004 in vascularized pinguecula

© 2025 MJH Life Sciences

All rights reserved.